C4 Therapeutics (CCCC) Return on Sales (2019 - 2026)

C4 Therapeutics has reported Return on Sales for 8 years, with the latest figure at 0.04% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.04%; the trailing twelve-month figure through Mar 2026 stood at 0.03% (changed 0.0% YoY), and the FY2025 full-year result was 0.03%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.04%, down from 0.02% in the prior quarter.
• The five-year high for Return on Sales was 0.01% in Q2 2024, with the low at 0.13% in Q2 2023.
• Average Return on Sales over 5 years is 0.06%, with a median of 0.04% recorded in 2026.
• Year-over-year, Return on Sales declined 12 bps in 2022 and rose 12 bps in 2024.
• Tracing CCCC's Return on Sales over 5 years: stood at 0.13% in 2022, then grew by 18 bps to 0.11% in 2023, then surged by 37 bps to 0.07% in 2024, then jumped by 72 bps to 0.02% in 2025, then sank by 121 bps to 0.04% in 2026.
• The last three Return on Sales figures came in at 0.04% (Q1 2026), 0.02% (Q4 2025), and 0.03% (Q3 2025), per Business Quant data.

Peer Comparison